Prove superiority for differential pricing, NPPA tells pharma companies

Multinational stent makers have asked the National Pharmaceutical Pricing Authority (NPPA) to consider differential pricing for drug eluting stents — ones that are coated with medicine which is slowly released into the artery to treat the diseased area — during a meeting on Monday.

The NPPA has said it will allow different prices for drug eluting stents only if the manufacturers can prove the superiority of stents, officials who attended the meeting told Business Standard.

“While multinational firms like Abbott, Boston Scientific, and Medtronic pushed for categorisation, domestic manufacturers told the NPPA that they want a higher ceiling price as the current